Stockscreener 앱 받기
22.88
1.69%
0.38
시간 외 거래:
22.99
0.11
+0.48%
전일 마감가:
$22.50
열려 있는:
$22.78
하루 거래량:
1.34M
Relative Volume:
0.78
시가총액:
$2.50B
수익:
-
순이익/손실:
$-183.79M
주가수익비율:
-11.06
EPS:
-2.0691
순현금흐름:
$-131.84M
1주 성능:
+14.29%
1개월 성능:
+1.78%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$22.48
$23.28
1주일 범위
$20.13
$23.28
52주 변동 폭
$14.62
$26.25
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
22.88 | 2.45B | 0 | -183.79M | -131.84M | -2.0691 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-10 | 개시 | Piper Sandler | Overweight |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated May 2026 - MarketBeat
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program - TradingView
Jefferies Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential - Seeking Alpha
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens - Yahoo Finance
Definium Therapeutics Nears Pivotal Earnings Call Tests - The Globe and Mail
Definium Therapeutics convenes lawmakers and researchers to advance psychedelic medicine discourse - Traders Union
DFTX Stock Price, Quote & Chart | DEFINIUM THERAPEUTICS INC (NASDAQ:DFTX) - ChartMill
Definium Therapeutics Advances DT120 ODT for GAD and MDD With Promising Phase 3 Data and Billion-Dollar Market Potential - Minichart
Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline - TipRanks
Definium Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash - TradingView
Definium Therapeutics (NASDAQ: DFTX) maps DT120 Phase 3 path and 2026 data - Stock Titan
Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting - Traders Union
Definium Therapeutics (DFTX) Institutional Ownership 2026 - MarketBeat
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - Reuters
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Deep Track entities disclose 3.01% stake in Definium Therapeutics (DFTX) - Stock Titan
Definium Therapeutics (DFTX) stock gains after hours: Here's what's driving the move - MSN
H.C. Wainwright Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Definium Therapeutics (DFTX) Is Down 6.0% After Starting Second Phase 3 DT120 Trial in MDDHas The Bull Case Changed? - Sahm
Definium Therapeutics launches pivotal Phase 3 Ascend trial in major depressive disorder - Traders Union
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Doses First Patient in Phase 3 Ascend Trial of DT120 ODT (LSD) for Major Depressive Disorder - Minichart
Definium Therapeutics (DFTX) Begins Phase 3 Study for Major Depr - GuruFocus
Definium doses first patient in second phase 3 depression study - Investing.com UK
Definium Therapeutics Begins Patient Dosing in Ascend Phase 3 Depression Trial - marketscreener.com
Definium begins second Phase 3 trial for DT120 - TipRanks
Definium Therapeutics says first patient dosed in Ascend study - TipRanks
Definium Therapeutics doses first patient in Phase 3 Ascend trial of DT120 ODT for MDD - TradingView
Definium Therapeutics (DFTX) doses first patient in Ascend Phase 3 DT120 depression trial - Stock Titan
DFTX.O - Reuters
Definium Therapeutics announces first patient dosed in Ascend - marketscreener.com
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder - The Joplin Globe
Definium Therapeutics engages at Fierce Biotech Week with industry communications leaders - Traders Union
Definium Therapeutics Announces New Employee Inducement Grants - Yahoo Finance
Biotech Definium offers stock options to five new hires - Stock Titan
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $25 to $61 - Moomoo
Definium Therapeutics, Inc. (DFTX) Price To Cash Flow - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent? - Yahoo Finance
RBC Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $36 - Moomoo
DFTX Maintained by Piper Sandler -- Price Target Lowered to $48 - GuruFocus
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $36 to $48 - Moomoo
DFTX SEC FilingsDefinium Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Definium Therapeutics Inc (DFTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Definium Therapeutics Inc 주식 (DFTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
0.98%
0.12%
자본화:
|
볼륨(24시간):